Phase 1 12 trials
Phase 1
NCT03696784 Mar 2019 → Aug 2025 overdue B-cell non-Hodgkin lymphoma , immunoproliferative disorder , lymphatic system disorder UNC Lineberger Comprehensive Cancer Center
Active not recruiting
No outcome recorded
Phase 1
NCT03459170 Feb 2018 → Sep 2022 overdue hematopoietic and lymphoid cell neoplasm Bellicum Pharmaceuticals
Active not recruiting
No outcome recorded
Phase 1
NCT02744287 Nov 2016 → Mar 2023 castration-resistant prostate carcinoma , metastatic prostate carcinoma Regeneron Pharmaceuticals
Terminated
No outcome recorded
Phase 1
NCT02477878 Jul 2016 → Jan 2020 overdue leukemia , myelodysplastic syndrome , plasma cell myeloma Bellicum Pharmaceuticals
Active not recruiting
No outcome recorded
Phase 1
NCT02487459 Jul 2016 → Jun 2017 hematopoietic and lymphoid cell neoplasm Bellicum Pharmaceuticals
Withdrawn
No outcome recorded
Phase 1
NCT02786485 May 2016 → Dec 2018 leukemia , myelodysplastic syndrome , plasma cell myeloma Bellicum Pharmaceuticals
Withdrawn
No outcome recorded
Phase 1
NCT02231710 Feb → Sep 2015 bone marrow failure syndrome , hemoglobinopathy , hemophagocytic syndrome , immunodeficiency disease +1 Bellicum Pharmaceuticals
Terminated
No outcome recorded
Stop: Enrollment
Phase 1
NCT02107963 Feb 2014 → Aug 2016 melanoma , neuroblastoma , osteosarcoma National Cancer Institute (NCI)
Completed
No outcome recorded
Phase 1
NCT03016377 Mar 2012 → Sep 2025 overdue acute lymphoblastic leukemia , immunoproliferative disorder UNC Lineberger Comprehensive Cancer Center
Active not recruiting
No outcome recorded
Phase 1
NCT01494103 Nov 2011 → May 2029 expected Epstein-Barr virus infection , X-linked lymphoproliferative syndrome , acute lymphoblastic leukemia , acute myeloid leukemia +3 Baylor College of Medicine
Active not recruiting
No outcome recorded
Phase 1
NCT00868595 Apr 2009 → Jul 2011 castration-resistant prostate carcinoma Bellicum Pharmaceuticals
Completed
No outcome recorded
Phase 1
NCT00710892 Dec 2008 → Nov 2011 overdue acute lymphoblastic leukemia , chronic myeloid leukemia , myelodysplastic syndrome Baylor College of Medicine
Active not recruiting
No outcome recorded
Show 2 more trials Phase 1/2 6 trials
Phase 1/2
NCT02849886 Apr 2019 → Dec 2021 graft versus host disease , hematopoietic and lymphoid cell neoplasm Centre Hospitalier Universitaire de Besancon
Terminated
No outcome recorded
Stop: Enrollment
Phase 1/2
NCT02743611 Apr 2017 → Jul 2019 acute myeloid leukemia , myelodysplastic syndrome , uveal melanoma Bellicum Pharmaceuticals
Terminated
No outcome recorded
Phase 1/2
NCT02065869 Apr 2014 → Jun 2020 Diamond-Blackfan anemia , Fanconi anemia , acute lymphoblastic leukemia , childhood acute myeloid leukemia +5 Bellicum Pharmaceuticals
Terminated
No outcome recorded
Stop: Business
Phase 1/2
NCT03301168 Apr 2014 → May 2021 overdue acute lymphoblastic leukemia , aplastic anemia , childhood acute myeloid leukemia , hemoglobinopathy +3 Bellicum Pharmaceuticals
Active not recruiting
No outcome recorded
Phase 1/2
NCT01875237 Dec 2013 → Mar 2017 leukemia , myeloproliferative neoplasm , plasma cell myeloma M.D. Anderson Cancer Center
Terminated
No outcome recorded
Phase 1/2
NCT01744223 Mar 2013 → Oct 2019 overdue acute lymphoblastic leukemia , acute myeloid leukemia , myelodysplastic syndrome Bellicum Pharmaceuticals
Active not recruiting
No outcome recorded
Comparator or background therapy 21 trials
Phase 1
NCT07553390 Background Oct 2026 → Mar 2036 expected breast cancer M.D. Anderson Cancer Center
Not yet recruiting
No outcome recorded
Phase 1
NCT06984341 Background Jun 2026 → Nov 2033 expected systemic lupus erythematosus Genentech, Inc.
Not yet recruiting
No outcome recorded
Phase 1
NCT06014762 Background Apr 2024 → Mar 2029 expected high grade B-cell lymphoma , primary mediastinal large B-cell lymphoma Poseida Therapeutics, Inc.
Active not recruiting
No outcome recorded
Phase 1
NCT06066424 Background Oct 2023 → Apr 2038 expected cancer M.D. Anderson Cancer Center
Recruiting
No outcome recorded
Phase 1
NCT04960579 Background May 2022 → Mar 2029 expected plasma cell myeloma Poseida Therapeutics, Inc.
Active not recruiting
No outcome recorded
Phase 1
NCT05239143 Background Feb 2022 → Apr 2026 overdue breast cancer , colorectal cancer , gastric cancer , head and neck squamous cell carcinoma +5 Poseida Therapeutics, Inc.
Active not recruiting
No outcome recorded
Phase 1
NCT04249947 Background Feb 2020 → Sep 2024 adenoid cystic carcinoma , castration-resistant prostate carcinoma , mucoepidermoid carcinoma , salivary duct carcinoma +1 Poseida Therapeutics, Inc.
Terminated
No outcome recorded
Phase 1
NCT03807063 Background Jan → Dec 2020 B-cell chronic lymphocytic leukemia , CD4+/CD56+ hematodermic neoplasm , acute biphenotypic leukemia , bilineal acute myeloid leukemia +4 Fred Hutchinson Cancer Center
Withdrawn
No outcome recorded
Stop: Business
Phase 1
NCT03958656 Background Jun 2019 → Oct 2020 plasma cell myeloma National Cancer Institute (NCI)
Completed
No outcome recorded
Phase 1
NCT03741127 Background Oct 2018 → Aug 2032 expected plasma cell myeloma Poseida Therapeutics, Inc.
Active not recruiting
No outcome recorded
Phase 1
NCT02792114 Background Jun 2016 → Jun 2027 expected Her2-receptor negative breast cancer Memorial Sloan Kettering Cancer Center
Active not recruiting
No outcome recorded
Phase 1
NCT01823978 Background Apr 2013 → May 2016 castration-resistant prostate carcinoma Bellicum Pharmaceuticals
Completed
No outcome recorded
Phase 1/2
NCT07509008 Background Aug 2026 → Jul 2028 expected gastric adenocarcinoma M.D. Anderson Cancer Center
Recruiting
No outcome recorded
Phase 1/2
NCT07598955 Background Mar 2026 → Jun 2027 expected thymic carcinoma , thymoma Beijing Biotech
Recruiting
No outcome recorded
Phase 1/2
NCT03288493 Background Sep 2017 → Apr 2022 plasma cell myeloma Poseida Therapeutics, Inc.
Terminated
No outcome recorded
Phase 1/2
NCT03056339 Background Jun 2017 → Mar 2023 B-cell chronic lymphocytic leukemia M.D. Anderson Cancer Center
Completed
No outcome recorded
Phase 1/2
NCT03733249 Background Jan 2017 → Jun 2020 Diamond-Blackfan anemia , Fanconi anemia , acute lymphoblastic leukemia , childhood acute myeloid leukemia +5 Bellicum Pharmaceuticals
Terminated
No outcome recorded
Phase 2
NCT07164469 Background Dec 2026 → Sep 2031 expected Hodgkins lymphoma , large B-cell lymphoma M.D. Anderson Cancer Center
Not yet recruiting
No outcome recorded
Phase 2/3
NCT03699475 Background Dec 2018 → Jul 2019 acute myeloid leukemia , myelodysplastic syndrome Bellicum Pharmaceuticals
Terminated
No outcome recorded
Stop: Business
— NCT03639844 Background — Hurler syndrome , metachromatic leukodystrophy Bellicum Pharmaceuticals
No longer available
No outcome recorded
— NCT03594162 Background — acute lymphoblastic leukemia , immunoproliferative disorder UNC Lineberger Comprehensive Cancer Center
No longer available
No outcome recorded
Show 16 more trials